Results 141 to 150 of about 7,822 (173)
Syncytia Formation in Oncolytic Virotherapy [PDF]
Molecular Therapy - Oncolytics, 2019 Oncolytic virotherapy uses replication-competent virus as a means of treating cancer. Whereas this field has shown great promise as a viable treatment method, the limited spread of these viruses throughout the tumor microenvironment remains a major challenge. To overcome this issue, researchers have begun looking at syncytia formation as a novel method
Eric Bartee
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Oncolytic virotherapy: Challenges and solutions
Current Problems in Cancer, 2021Viruses as cancer therapies have attracted attention since the 19th century. Scientists observation that viruses can preferentially lyse cancer cells rather than healthy cells, created the field of oncolytic virology. Like other therapeutic strategies, oncolytic virotherapy has challenges, such as penetration into tumor bulk, anti-viral immune ...
Nasser Hashemi Goradel +5 more
openaire +2 more sources
Targeting gene-virotherapy of cancer [PDF]
Cell Research, 2006 Our purpose is to completely elimination of xenograft tumor in animal tumor model in order to work out a protocal for the cure of patient. Gene therapy and viral therapy for cancer have got some therapeutic effects, but both have no great breakthrough.
Xin Yuan Liu
exaly +3 more sources
2018
Oncolytic virotherapy is a kind of antitumor therapy using viruses with natural or engineered tumor-selective replication to intentionally infect and kill tumor cells. An early clinical trial has been performed in the 1950s using wild-type and non-engineered in vitro-passaged virus strains and vaccine strains (first generation oncolytic viruses ...
Daisuke, Watanabe, Fumi, Goshima
openaire +2 more sources
Oncolytic virotherapy is a kind of antitumor therapy using viruses with natural or engineered tumor-selective replication to intentionally infect and kill tumor cells. An early clinical trial has been performed in the 1950s using wild-type and non-engineered in vitro-passaged virus strains and vaccine strains (first generation oncolytic viruses ...
Daisuke, Watanabe, Fumi, Goshima
openaire +2 more sources
Virotherapy of Neuroendocrine Tumors
Neuroendocrinology, 2012Most patients with small intestinal neuroendocrine tumors (SI-NETs), also referred to as midgut carcinoids, present with systemic disease at the time of diagnosis with metastases primarily found in regional lymph nodes and the liver. Curative treatment is not available for these patients and there is a need for novel and specific therapies.
openaire +2 more sources
Introduction to Oncolytic Virotherapy
2019Oncolytic viruses exploit key hallmarks of cancer for replication in malignant cells, leading to tumor cell lysis, modulation of the tumor microenvironment and in situ vaccination effects. Diverse virus platforms have been developed as oncolytic vectors and designed for improved tumor specificity, intratumoral spread, therapeutic gene delivery and ...
Christine E, Engeland, John C, Bell
openaire +2 more sources
Oncolytic virotherapy reaches adolescence
Pediatric Blood & Cancer, 2010AbstractLytic viruses kill cells as a consequence of their normal replication life cycle. The idea of harnessing viruses to kill cancer cells arose over a century ago, before viruses were even discovered, from medical case reports of infections associated with cancer remissions.
Adrienne M, Hammill +2 more
openaire +2 more sources
Oncolytic virotherapy for multiple myeloma
Expert Opinion on Biological Therapy, 2008Current therapies for multiple myeloma (MM) are not curative, thus novel targeted therapeutics are being developed. One such targeted therapy is oncolytic virotherapy, wherein viruses specifically infect and kill the malignant plasma cells, leaving normal cells intact.This review provides an overview of the mechanisms and results of the oncolytic ...
Amaalia E, Stief, J Andrea, McCart
openaire +2 more sources
Systemic virotherapy for multiple myeloma
Expert Opinion on Biological Therapy, 2017The multiple myeloma (MM) treatment scenario has changed considerably over the past few years. Several novel targeted therapies are currently under consideration including oncolytic virotherapy. Areas covered: This review provides an analysis of the mechanisms of action of virotherapy, and summarizes the preclinical and clinical studies of systemic ...
Stefania, Oliva +3 more
openaire +2 more sources